自杀基因
胸苷激酶
基因组编辑
细胞
细胞疗法
计算生物学
诱导多能干细胞
细胞周期蛋白依赖激酶1
基因
基因组工程
生物
遗传增强
单纯疱疹病毒
基因组
细胞周期
遗传学
病毒
胚胎干细胞
作者
Qin Liang,Claudio Monetti,Maria V. Shutova,Eric Neely,Sabiha Hacibekiroglu,Huijuan Yang,Chris Kim,Puzheng Zhang,Chengjin Li,Kristina Vintersten Nagy,Maria Mileikovsky,István Gyöngy,Hoon‐Ki Sung,András Nagy
出处
期刊:Nature
[Nature Portfolio]
日期:2018-11-01
卷期号:563 (7733): 701-704
被引量:125
标识
DOI:10.1038/s41586-018-0733-7
摘要
Human pluripotent cell lines hold enormous promise for the development of cell-based therapies. Safety, however, is a crucial prerequisite condition for clinical applications. Numerous groups have attempted to eliminate potentially harmful cells through the use of suicide genes1, but none has quantitatively defined the safety level of transplant therapies. Here, using genome-engineering strategies, we demonstrate the protection of a suicide system from inactivation in dividing cells. We created a transcriptional link between the suicide gene herpes simplex virus thymidine kinase (HSV-TK) and a cell-division gene (CDK1); this combination is designated the safe-cell system. Furthermore, we used a mathematical model to quantify the safety level of the cell therapy as a function of the number of cells that is needed for the therapy and the type of genome editing that is performed. Even with the highly conservative estimates described here, we anticipate that our solution will rapidly accelerate the entry of cell-based medicine into the clinic.
科研通智能强力驱动
Strongly Powered by AbleSci AI